Interojo Co

Interojo Co Capital Expenditures

The Capital Expenditures (CapEx) of Interojo Co (119610.KQ) as of Oct 22, 2026 is -6.93 B KRW. In the previous year, Capital Expenditures (CapEx) was -3.31 B KRW — a change of 109.29% (lower).

Capital Expenditures

-6.93 BKRW

YoY

109.29%

Last updated:

Capital Expenditures (CapEx) of Interojo Co is 2025 -6.93 B KRW. Capital Expenditures (CapEx) of Interojo Co was 2024 -3.31 B KRW. It decreases by 109.29% lower compared to the previous year.

The Interojo Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-13.26 B KRW
Jan 1, 2019
-15.89 B KRW
Jan 1, 2020
-26.51 B KRW
Jan 1, 2021
-10.71 B KRW
Jan 1, 2022
-17.13 B KRW
Jan 1, 2023
-8.27 B KRW
Jan 1, 2024
-3.31 B KRW
Jan 1, 2025
-6.93 B KRW
The Interojo Co Capital Expenditures history
YEARCapital ExpendituresYoY
-6.93 BKRW+109.29%
-3.31 BKRW-59.99%
-8.27 BKRW-51.71%
-17.13 BKRW+59.98%
-10.71 BKRW-59.62%
-26.51 BKRW+66.89%
-15.89 BKRW+19.79%
-13.26 BKRW+141.84%
-5.48 BKRW+12.05%
-4.89 BKRW-46.37%
-9.13 BKRW+96.84%
-4.64 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interojo Co Stock analysis

What does Interojo Co do? Interojo Co Ltd manufactures and sells contact lenses including silicone hydrogel lenses, sodium hyaluronate lenses, frequent replacement lenses, conventional lenses, toric lenses, multifocal vision lenses, color lenses, therapy and bandage lenses, and rigid gas permeable (RGP) contact lenses along with solutions. The company distributes its products in domestic and overseas markets, targeting both retail consumers and healthcare providers who purchase lenses for patient use. Its product range caters to diverse vision correction needs, from standard to specialized medical applications, with solutions supporting lens care and usage. The firm's primary revenue streams come from the sale of contact lenses and associated solutions to customers in both domestic and international markets. Products like silicone hydrogel lenses and RGP contact lenses represent key offerings for everyday wear and specialized vision correction, while therapy and bandage lenses serve medical applications requiring professional oversight. The company's domestic market presence complements its overseas distribution, ensuring broad accessibility across different customer segments. Interojo Co Ltd's business model focuses on direct sales of its comprehensive product portfolio to end-users and healthcare institutions. The company's product lines address various vision correction scenarios, from routine daily use with frequent replacement lenses to advanced medical needs with therapy lenses. By maintaining a diverse range of contact lenses and solutions, the company serves both consumer and professional markets without relying on third-party partnerships or additional services. Interojo Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interojo Co stock

Capital Expenditures (CapEx) of Interojo Co is -6.93 B KRW in 2025.

Capital Expenditures (CapEx) of Interojo Co changed from -3.31 B KRW to -6.93 B KRW, representing a 109.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Interojo Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Interojo Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Interojo Co

All Key Metrics — Interojo Co